uniQure (NASDAQ:QURE) Given Consensus Rating of “Buy” by Analysts

Shares of uniQure (NASDAQ:QURE) have been assigned a consensus recommendation of “Buy” from the ten ratings firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $33.88.

QURE has been the subject of several recent research reports. Mizuho boosted their price objective on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. Royal Bank of Canada lifted their target price on shares of uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. StockNews.com raised uniQure to a “sell” rating in a research note on Wednesday, December 11th. Finally, Cantor Fitzgerald raised their price target on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 10th.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. RTW Investments LP acquired a new position in uniQure during the 3rd quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. boosted its holdings in uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares during the last quarter. Atria Investments Inc bought a new position in uniQure in the third quarter valued at $53,000. Quarry LP acquired a new stake in uniQure in the 3rd quarter valued at $58,000. Finally, Vanguard Personalized Indexing Management LLC lifted its position in uniQure by 21.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,306 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Stock Performance

Shares of uniQure stock opened at $15.92 on Thursday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The firm has a 50 day simple moving average of $10.83 and a 200 day simple moving average of $7.85. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18. The firm has a market cap of $775.99 million, a P/E ratio of -3.21 and a beta of 0.41.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The company had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. Sell-side analysts predict that uniQure will post -3.82 earnings per share for the current fiscal year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.